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SUPERIOR COURT
CIVIL ACTION
DOCKET NO.

STATE OF MAINE
KENNEBEC, SS.

STATE OF MAINE

Plaintiff,
v.
ELI LILLY AND COMPANY,
Defendant.

1.

)
)
)
)
)
)
)
)
)
)
)

COMPLAINT FO R INJUNCTIVE
AND OTHER RELIEF

Plaintiff, State o f Maine, by and through its Attorney General G. Steven Rowe,

brings this action complaining o f Defendant ELI LILLY AND COMPANY, an Indiana
corporation, for violating the Maine Unfair Trade Practices Act as follows:

PARTIES
2.

Plaintiff, State o f Maine, is represented by the Attorney General who brings this

action in the public interest pursuant to 5 M.R.S.A. § 209.
3.

Defendant ELI LILLY AND COMPANY (“Lilly” or “Defendant”) is an Indiana

corporation that conducts business nationwide, including in the State o f Maine; its principal
place o f business is Lilly Corporate Center, Indianapolis, Indiana 46285. Eli Lilly, at all times
relevant hereto, engaged and trade and commerce within the meaning o f the Maine Unfair Trade
Practices Act, 5 M.R.S.A. § 205-A et seq., in the State o f Maine.

JURISDICTION AND VENUE
4.

This court has jurisdiction over the subject matter and defendants of this action

pursuant to 5 M.R.S.A. § 209.
5.

In accordance with 5 M.R.S.A. § 209, venue is proper in this court.

6.

The Maine Unfair Trade Practices Act, 5 M.R.S.A. § 205-A et seq., makes

unlawful unfair or deceptive acts or practices in the conduct of any trade or commerce, and
authorizes the Attorney General to bring enforcement actions to obtain permanent injunctive
relief and recover restitution and civil penalties up to $ 10,000 for each intentional violation. 5
M.R.S.A. § 207, 209.
BACKGROUND
7.

Zyprexa belongs to a class o f drugs traditionally used to treat schizophrenia and

commonly referred to as “atypical antipsychotics.” When these drugs were first introduced to
the market in the 1990s, it was hypothesized that they might be used as long-term treatment for
schizophrenia without posing the same risks as first-generation antipsychotics.

More

specifically, experts thought that atypical antipsychotics would be less likely to produce
extrapyramidal symptoms (“EPS”) and tardive dyskinesia (“I D ”).
8.

While these drugs may reduce the risk of EPS and TD associated with first-

generation antipsychotics, they also produce dangerous side effects, including weight gain,
hyperglycemia, diabetes, cardiovascular complications, and other severe conditions. Zyprexa
has been shown to pose a high risk of weight gain, hyperglycemia, and diabetes.
DEFENDANT’S COURSE OF CONDUCT
9.

Lilly began marketing Zyprexa to health care professionals for the treatment of

schizophrenia in 1996. Since then, the Food and Drug Administration (“FDA”) has approved
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Zyprexa for, inter alia, the treatment o f acute mixed or manic episodes o f bipolar I disorder and
for maintenance treatment in bipolar disorder.
10.

In 2001, Lilly engaged in an aggressive marketing campaign called “Viva

Zyprexa!” As part o f that campaign, the company marketed Zyprexa for a number o f uses for
which it was not approved by the FDA. For example, Lilly marketed Zyprexa for pediatric use,
for use at high dosage levels, for the treatment o f symptoms rather than diagnosed conditions,
and for the treatment and/or chemical restraint of patients suffering from dementia.
11.

Through this Viva Zyprexa! campaign, and all o f the company’s efforts to

promote Zyprexa for uses for which it was not approved by the FDA, Lilly misrepresented the
drug’s approved uses, its safety, and its effectiveness.

VIOLATIONS OF LAW
12.

The allegations contained in paragraphs 1-11 are incorporated herein by

reference.
13.

The Defendant, in the course of advertising, soliciting, selling, promoting and

distributing the prescription drug Zyprexa, has engaged in a course o f trade or commerce which
constitutes unfair or deceptive acts or practices, and is therefore unlawful under the Maine Unfair
Trade Practices Act by misrepresenting that Zyprexa had characteristics, uses, benefits, and
qualities that it does not have.

PRAYER FOR RELIEF
WHEREFORE, the plaintiff prays that this honorable Court enter an Order:
A.

Issuing a permanent injunction prohibiting Defendant, its agents, employees,
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and all other persons and entities, corporate or otherwise, in active concert or participation
with any o f them, from engaging in unfair or deceptive conduct;
B.

Ordering Defendant to pay all costs for the prosecution and investigation of this

action, as provided by 5 M.R.S A . § 209;
C.

Ordering Defendant to pay civil penalties for each and every violation of the

Maine Unfair Trade Practices Act; and
D.

Granting such other and further relief as the Court deems equitable and proper.

Respectfully submitted,
PLAINTIFF STATE OF MAINE

G. STEVEN ROWE
ATTORNEY GENERAL

Dated: October 7,2008
cnnstina M. Moyian
Assistant Attorney General
Department o f Attorney General
6 State House Station
Augusta, Maine 04333-0006
Maine Bar No. 7095
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STATE OF MAINE
SUPERIOR COURT

DISTRICT COURT
Location_________
Docket N o._______

KENNEBEC.
Docket No. _

STATE OF MAINE___________
Plaintiff
APPLICATION FOR TRANSFER TO
BUSINESS AND CONSUMER DOCKET

v.

ELI LILLY AND COMPANY______
Defendant

I/We submit this application for transfer o f the above-captioned case to the BCD, based on the following information:
Plaintiff

NAME OF EACH PARTY SUBMITTING THIS APPUCATION:

Defendant

State of Maine

m

□

Eli Lilly and Company

□

a

□

□

□

□

1. Is at least one party a business entity?

[5 Yes

Q No

2. List all plaintiffs and their attorney:

ATTORNEY (NAME AND ADDRESS)
Christina Moylan-, AÄG
Office of- the At-tcrnev General
6 State House Station
Aiignstfl Mai np (1 4 3 3 3 —0 0 0 6 __________

PLAINTIFFS)
State of Maine

3. List all defendants and their attorney:

ATTORNEY (NAME AND ADDRESS)
Nicholas Gess, Esq.
Bingham MrC.ufr.hen. T.T.P____
202Ö K s t . m

DEFENDANT(S)
Eli Lilly and Company

4. List any other cases with which this case is or may need be consolidated or coordinated:

DOCKETNUMBER

CASE CAPTION

BCD-001

1

CURRENT COURT LOCATION

S. What is the subject matter of the primary cause of action in this case:
□
□

u
□
□
□
□

u
□

Breach o f Contract
Breach o f Fiduciary Duty
80B Appeal involving a business entity
Internal governance of a business entity
Shareholder derivative action
Intellectual property
U.C.C. transactions
Antitrust or other trade regulations
Other (describe):

□
□
□
□
□
□

m
□

Breach of Warranty
Class Action
80C Appeal involving a business entity
Securities transactions
Confidential or trade secret
Financial transactions
Unfair trade practices
Commercial real estate

NOT YET
DETERMINED

6. What is the status of this case:
a.
b.
c.
d.
e.
f.
g.

h.
i.
j.
k.

Are the pleadings closed? ............................................
Is discovery completed? ................................................
Is class action status sought?.........................................
Scheduled for trial? If so, w hen?_________________
Pretrial held?.................................................................
Case management conference held? ..........
Jury trial? ....................................................................
Bench trial?....................................................................
ADR been attempted?.................................................
Is file sealed (partial / entire)?.......................................
Will post-judgment judicial supervision be needed? ...

7. What Is the estimated length of trial (in days)?

YES
LD

□

□
□
□
□

CD

□
□

Q
CD

□

CD

□
□

CD

□

CD

none expected (settlement submitted for approval)

8. Identify nature and number of any pending pretrial motions:

9. Identify any novel and/or complex legal issues in this case:

10. Do all of the parties appearing in the case agree to a transfer?

none
none

IX] YES

CD NO

CERTIFICATION OF SERVICE BY ATTORNEY OR PARTY SUBMITTING APPLICATION
I hereby certify that a copy was mailed/delivered to all counsel and pro se parties of record on this date
SIGNED:

.

DATE

vZi ¿ v * —

fff-7 ' 02

------------------------------------------------------------------- -—

ORDER (For BCD Court Use Only)
The above Application having been considered, it is ORDERED as follows:

CD The case is ACCEPTED for transfer. The case file shall be transferred forthwith from the court in which the case is now
pending to the BCD.
CD The case is NOT ACCEPTED for transfer.
DATE

SIGNED (BCD Justice/Judge)

PLEASE NOTE THE FOLLOWING:
A. Failure to supply complete and accurate information may disqualify a case for consideration for transfer to
the BCD.
B. Information that does not fit on this form should be attached on a separate sheet and numbered to
correspond to the inquiries on the form.
C. This application should he filed with the court in which the case is currently pending.
BCD-001
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STATE OF MAINE

SUPERIOR COURT

KENNEBEC, SS.

CIVIL ACTION

Docket No.
STATE OF MAINE,

-0 2 ^ X 1

BOW ËrCV-CS-æ
Plaintiff

v.
CONSENT JUDGMENT
ELI LILLY AND COMPANY,

Defendant

PREAMBLE
A.
The Attorneys General o f the States o f Alabama, Arizona, California, Delaware,
District of Columbia, Florida, Hawaii, Illinois, Indiana, Iowa, Kansas, Maine, Maryland,
Massachusetts, Michigan, Missouri, Nebraska, Nevada, New Jersey, New York, North Carolina,
North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee,
Texas, Vermont, Washington, and Wisconsin, (collectively, the “Attorneys General,” and the
“AGs”), conducted an investigation under the State Consumer Protection Laws regarding certain
Eli Lilly and Company (“Eli Lilly” or “Lilly”) practices concerning Zyprexa®; and
B.
The Plaintiff, State o f Maine, acting through Attorney General G. Steven Rowe,
has brought this action pursuant to the Maine Unfair Trade Practices Act, 5 M.R.S.A. § 205-A et
seq., having filed a complaint against Eli Lilly; and
C.
Eli Lilly is willing to enter into a Consent Judgment (the “Judgment”) regarding
its promotional practices, sampling practices, dissemination o f information, and remuneration to
Health Care Professionals regarding Zyprexa® (“Covered Conduct”) in order to resolve the
AGs’ investigation under the State Consumer Protection Laws and arrive at a complete and total
settlement and resolution o f any disagreement as to the matters addressed in this Judgment and
thereby avoid unnecessary expense, inconvenience, and uncertainty. Eli Lilly denies the
allegations o f the Complaint and denies having violated the Unfair Trade Practices Act; and
D.
The Parties have agreed to resolve the issues raised by the Covered Conduct by
entering into this Judgment. Eli Lilly is entering into this Judgment solely for the purpose of
settlement and nothing contained herein may be taken as or construed to be an admission or
concession of any violation o f law or regulation, or of any other matter o f fact or law, or o f any

liability or wrongdoing, all of which Eli Lilly expressly denies. Lilly does not admit any
violation o f the State Consumer Protection Laws, and does not admit any wrongdoing that was or
could have been alleged by any Attorney General before the date o f the Judgment under those
laws. No part o f this Judgment, including its statements and commitments, shall constitute
evidence o f any liability, fault, or wrongdoing by Eli Lilly. Except in an action brought by an
Attorney General to enforce this Judgment, this Judgment shall not be construed or used as a
waiver or limitation o f any defense otherwise available to Eli Lilly, including, but not limited to
the defense o f federal preemption, in other matters, or o f Eli Lilly’s right to defend itself from, or
make any arguments in, any other matter, including, but not limited to, any investigation or
litigation relating to the existence, subject matter or terms o f this Judgment. This Judgment is
made without trial or adjudication o f any issue of fact or law or finding o f wrongdoing or
liability o f any kind. It is the intent o f the Parties that this Judgment shall not be admissible in
any other matter, including, but not limited to, any investigation or litigation, or bind Eli Lilly in
any respect other than in connection with the enforcement o f this Judgment. No part of this
Judgment shall create a private cause o f action or confer any right to any third party for violation
o f any federal or state statute except that a State may file an action to enforce the terms of this
Judgment. All obligations undertaken by Eli Lilly in this Judgment shall apply prospectively;
and nothing contained herein prevents or prohibits the use of this Judgment for purposes of
enforcement by the AGs; and
E.
The AGs have reviewed the terms o f the Judgment and find that such terms serve
the public interest; and
F.
This Judgment (or any portion thereof) shall in no way be construed to prohibit
Eli Lilly from making representations with respect to Zyprexa that are permitted under Federal
law or in Labeling for the drug under the most current draft or final standard promulgated by the
FDA or the most current draft or final FDA Guidances for Industry, or permitted or required
under any Investigational New Drug Application, New Drug Application, Supplemental New
Drug Application, or Abbreviated New Drug Application approved by FDA, so long as the
representation, taken in its entirety, is not false, misleading or deceptive; and
IT IS HEREBY ORDERED that:
DEFINITIONS
The following definitions shall be used in construing this Judgment:
1.
“Clinically Relevant Information” shall mean information that reasonably
prudent clinicians would consider relevant when making prescribing decisions regarding
Zyprexa.
2.
“Consultant” or “Consulting” shall mean a non-Lilly Health Care
Professional engaged to advise regarding marketing or promotion o f Zyprexa.
3.
“Effective Date” shall mean the date on which a copy o f this Judgment,
duly executed by Lilly and by the Signatory Attorney General, is approved by, and becomes a
Judgment of, the Court or on November 1st, 2008, whichever is later.

2

(

f

4.
“Eli Lilly and Company” shall mean Eli Lilly and Company, including all
o f its affiliates, subsidiaries and divisions, predecessors, successors and assigns doing business in
the United States.
5.
“FDA Guidances for Industry” shall mean draft or final documents
published by the United States Department of Health and Human Services, Food and Drug
Administration (“FDA”) that represent the FDA’s thinking on a topic.
6.
“Health Care Economic Information” shall mean data and other
information relating to the inputs and outcomes o f health care therapies and services, including,
but not limited to, the price, cost-effectiveness, and quality o f life implications of Zyprexa.
7.
“Health Care Professional” or “HCP” shall mean any physician or other
health care practitioner who is licensed to provide health care services or to prescribe
pharmaceutical products.
8.
“Labeling” shall mean all FDA-approved labels, which are a display of
written, printed, or graphic matter upon the immediate container o f any article, and other written,
printed, or graphic matters (a) upon any article or any o f its containers or wrappers, or (b)
accompanying such article.
9.
“Lilly Grant Office” shall mean the U.S.-based organization within Eli
Lilly responsible for oversight o f the grant process, including the acceptance, review, and
payment o f all non-clinical grant requests.
10.
“Lilly Legal” shall mean personnel o f the Lilly Law Division or its
designee providing legal advice to Lilly.
11.
“Lilly Marketing” shall mean Lilly personnel assigned to the Lilly U.S.
Zyprexa marketing team.
12.
“Lilly Medical” shall mean Lilly personnel assigned to the Lilly U.S.
medical organization.
13.
“Lilly Non-Medical” shall mean Lilly personnel other than Lilly personnel
assigned to the U.S. Zyprexa medical organization.
14.
“Lilly Regulatory” shall mean Lilly personnel or their designee
responsible for Lilly’s adherence with FDA regulations.
15.

“Lilly Sales” shall mean the Lilly sales force responsible for U.S. Zyprexa

sales.
16.
“Medical Letter” shall mean a non-promotional, scientific communication
to address Unsolicited Requests for medical information from HCPs.
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17.
“Medical Reference” shall mean a non-promotional reference
communication that is used for responding to or answering a HCP’s Unsolicited Request for
medical information.
18.
“Multistate Executive Committee” shall mean the Attorneys General and
their staffs representing Arizona, California, Florida, Illinois, Ohio, Oregon, Texas and Vermont.
19.
“Multistate Working Group” shall mean the Attorneys General and their
staff representing Alabama, Arizona, California, Delaware, District o f Columbia, Florida,
Hawaii, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Massachusetts, Michigan, Missouri,
Nebraska, Nevada, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma,
Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington,
and Wisconsin.
20.
“Off-Label” shall mean a use not consistent with the indications section of
the Zyprexa Labeling approved by the FDA at the time information regarding such use was
communicated.
21.

“Parties” shall mean Lilly and the Signatory Attorney General.

22.
“Promotional,” “Promoting” or “Promote” shall mean claims to HCPs
about Zyprexa intended to increase sales or attempt to influence prescribing practices o f the
HCPs.
23.
“Promotional Materials” shall mean any item with the product name, logo,
or message used to Promote Zyprexa.
24.
“Promotional Slide Kit” shall mean Promotional Materials regarding
Zyprexa in the form of a slide kit for use in speaker programs.
25.
Promote Zyprexa.

“Promotional Speaker” shall mean a non-Lilly HCP speaker used to

26.
“Reprints Containing Off-Label Information” shall mean articles or
reprints from a peer reviewed journal or reference publication describing an Off-Label use of
Zyprexa.
27.
“Signatory Attorney General” shall mean the Attorney General of Maine,
or his authorized designee, who has agreed to this Judgment.
28.
“State Consumer Protection Laws” shall mean the consumer protection
laws under which the Attorneys General have conducted the investigation, ALABAMA Deceptive Trade Practices Act, Ala Code § 8-19-1 et seq.; ARIZONA - Consumer Fraud Act,
A.R.S. § 44-1521, et seq.; CALIFORNIA - Bus. & Prof. Code, §§ 17200 et seq., and 17500 et
seq.; DELAWARE - Consumer Fraud Act, 6 Del.C. Section 2511, et seq.; DISTRICT OF
COLUMBIA - Consumer Protection Procedures Act, D.C. Code § 28-3901, et seq.; FLORIDA Deceptive and Unfair Trade Practices Act, Fla. Stat. Ch. 501.201 et seq.; HAWAII - Uniform
Deceptive Trade Practice Act, Haw. Rev, Stat. Ch. 481A and Haw. Rev. Stat. § 480-2.;
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ILLINOIS - Consumer Fraud and Deceptive Business Practices Act, 815 ILCS § 505/1 et seq.;
INDIANA - Deceptive Consumer Sales Act, Ind. Code § 24-5-0.5-1 et seq.; IOWA - Iowa
Consumer Fraud Act, Iowa Code Section 714.16; KANSAS - Consumer Protection Act, K.S.A.
50-623 et seq.; MAINE - Unfair Trade Practices Act, 5 M.R.S.A. § 207 et seq.; MARYLAND Consumer Protection Act, Md. Code Ann., Com. Law § 13-101 et seq.; MASSACHUSETTS Consumer Protection Act, M.G.L. c. 93A et seq.; MICHIGAN - Michigan Consumer Protection
Act, MCL 445.901 et seq.; MISSOURI - Missouri Merchandising Practices Act, Mo. Rev. Stat.
§ 407.010 et seq.; NEBRASKA - Uniform Deceptive Trade Practices Act, NRS §§ 87-301 et
seq.; NEVADA - Deceptive Trade Practices Act, Nevada Revised Statutes 598.0903 et seq.;
NEW JERSEY - New Jersey Consumer Fraud Act, 56:8-1 et seq.; NEW YORK - General
Business Law Article 22-A Sections 349, 350 and Executive Law 63 (12); NORTH
CAROLINA - Unfair and Deceptive Trade Practices Act, N.C. Gen. Stat. § 75-1.1 et seq.;
NORTH DAKOTA -Unlawful Sales or Advertising Practices, N.D. Cent. Code. § 51-15-02 et
seq.; OHIO- Consumer Sales Practices Act, R.C. 1345.01, et seq.; OKLAHOMA - Oklahoma
Consumer Protection Act 15 O.S. §§ 751 et seq.; OREGON - Unlawful Trade Practices Act,
ORS 646.605 to 646.656; PENNSYLVANIA - Unfair Trade Practices and Consumer Protection
Law, 73 P.S. § 201-1 et seq.; RHODE ISLAND - R.I. Gen. L. § 6-13.1-1 et seq.; SOUTH
DAKOTA - Deceptive Trade Practices Act, S.D. Codified Laws § 37-24, et seq.; TENNESSEE Tennessee Consumer Protection Act, Tenn. Code Ann. §§ 47-18-101 et seq.; TEXAS Deceptive Trade Practices - Consumer Protection Act, Tex. Bus. and Com. Code § 17.47, et seq.;
VERMONT - Consumer Fraud Act, 9 V.S.A. § 2451 et seq.; WASHINGTON - Unfair Business
Practices/Consumer Protection Act, R.C.W. 19.86 et seq.; WISCONSIN - Wis. Stat. § 100.18
(Fraudulent Representations).
29.
“Unsolicited Request” shall mean a request for information regarding
Zyprexa from a HCP communicated to an agent o f Lilly that has not been prompted.
30.
“Zyprexa®” shall mean all FDA approved drug formulations containing
olanzapine as its sole active ingredient and Promoted by Lilly.
COMPLIANCE PROVISIONS
I.

Promotional Activities

A.
Lilly shall not make any written or oral claim that is false, misleading or
deceptive regarding Zyprexa.
B.
For six years from the Effective Date o f this Judgment, Lilly shall not Promote
Zyprexa for Off-Label uses.
C.
For six years from the Effective Date o f this Judgment, Lilly shall not present
patient profiles/types based on selected symptoms o f the FDA-approved indication(s) when
promoting Zyprexa, unless:
1.
The drug’s specific FDA-approved indication(s) being Promoted is/are
stated clearly and conspicuously in the same spread (i.e., on the same page or on a facing page)
in Promotional Materials as references to selected symptoms.
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a.

W ith respect to Promotional Slide Kits:
(i)

Lilly shall state clearly and conspicuously the FDAapproved indication(s) on the same slide in which selected
symptoms are first presented;

(ii)

Lilly shall include a short-hand reference to the statement
described in Section I.C.l.a.(i) on the same slide as each
subsequent reference to selected symptoms (e.g., “See
complete list o f FDA-approved indications at p. X”); and

(iii)

Lilly shall require any presenter o f Lilly’s Promotional
Slide Kits to present the statement required in Section
I.C.l.a.(i), as part o f the mandatory slides.

2.
Promotional Materials have a reference indicating that the full
constellation o f symptoms and the relevant diagnostic criteria are available in the Diagnostic and
Statistical Manual o f Mental Disorders (DSM-IV or current version), where applicable.
II.

Dissemination o f Medical Information
A.

General Terms

1.
The content of Lilly’s communications concerning Off-Label uses of
Zyprexa shall not be false, misleading or deceptive.
B.

Medical Letters and Medical References

1.
The following subsections shall be effective for six years from the
Effective Date o f this Judgment.
2.
Lilly Medical shall have ultimate responsibility for developing and
approving the medical content for all Medical Letters and Medical References regarding
Zyprexa, including any that may describe Off-Label information. Additional approvals may be
provided by Lilly Regulatory and Lilly Legal. Lilly shall not distribute any such materials
unless:
a.

Clinically Relevant Information is included in these materials to
provide scientific balance.

b.

Data in these materials are presented in an unbiased, nonPromotional manner.

c.

These materials are distinguishable from sales aids and other
Promotional Materials.

3.
Lilly Sales and Lilly Marketing personnel shall not develop the medical
content of Medical References or Medical Letters regarding Zyprexa. This provision does not
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prohibit Lilly Sales or Lilly Marketing personnel from suggesting topics for Medical Letters or
Medical References.
4.
Lilly Sales representatives shall not distribute Medical References or
Medical Letters regarding Zyprexa.
5.
Lilly shall not knowingly disseminate any Medical Letter describing any
Off-Label use of Zyprexa that makes any false or misleading representation regarding Zyprexa
or any false or misleading statement concerning a competing product.
C.

Responses to Unsolicited Requests for Off-Label information

1.
The following subsections shall be effective for six years from the
Effective Date of this Judgment.
2.
In responding to an Unsolicited Request for Off-Label information
regarding Zyprexa, including any request for a specific article related to Off-Label uses, Lilly
shall advise the requestor that the request concerns an Off-Label use and inform the requestor of
the drug’s FDA-approved indication(s) and/or dosage and other relevant Labeling information.
3.
If Lilly elects to respond to an Unsolicited Request for Off-Label
information from a HCP regarding Zyprexa, Lilly Medical personnel shall provide specific,
accurate, objective, and scientifically balanced responses. Any such response shall not Promote
Zyprexa for an Off-Label use.
4.
Any written response to an Unsolicited Request for Off-Label information
regarding Zyprexa shall include:
a.

an existing Medical Letter prepared in accordance with Section

n.B;
b.

a Medical Letter or other document such as slides prepared in
response to the request in accordance with Section II.B; or

c.

a report containing the results of a reasonable literature search
using terms from the request.

5.
Lilly Non-Medical personnel may not respond in writing to an Unsolicited
Request for Off-Label information regarding Zyprexa.
6.
Lilly Non-Medical personnel may respond orally to an Unsolicited
Request for Off-Label information regarding Zyprexa from a HCP only by informing the HCP of
the presence or absence o f published studies concerning the Off-Label topic or acknowledge
whether the topic is an area o f research, and by offering to request on behalf o f the HCP that a
Medical Letter or other information set forth above in II.C.4 be sent to the HCP in follow up.
Lilly Non-Medical personnel shall not characterize, describe, identify, name, or offer any
opinions about or summarize any such Off-Label information.
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Reprints

1.
The following subsections shall be effective for six years from the
Effective Date o f this Judgment.
2.

Reprints Containing Off-Label Information
a.

Lilly Medical shall be responsible for the identification, selection,
approval and dissemination of Reprints Containing Off-Label
Information regarding Zyprexa.

b.

Reprints Containing Off-Label Information regarding Zyprexa:

c.

(i)

shall be accompanied by the full prescribing information
for the product and contain a disclosure in a prominent
location, which would include the first page or as a cover
page where practicable, indicating that the article may
discuss Off-Label information; and

(ii)

shall not be referred to or used in a Promotional manner.

Reprints Containing Off-Label Information regarding Zyprexa may
only be disseminated by Lilly Medical personnel to HCPs. Lilly
Non-Medical personnel shall not disseminate these materials to
HCPs, absent the exception described below in (i).
(i)

In the event o f an extraordinary circumstance in which there
is a clinical necessity to have Lilly Non-Medical personnel
disseminate a Reprint Containing Off-Label Information
directly to HCPs, the President o f LillyUSA may approve a
Clinical Necessity Exception to the prohibition described in
Section II.D.2.C. above for that Reprint Containing OffLabel Information.

(ii)

If the Clinical Necessity Exception is invoked, Lilly will
notify each Signatory Attorney General o f its intent to
invoke the Clinical Necessity Exception at least 30 business
days prior to disseminating through Lilly Sales
representatives of any Reprint Containing Off-Label
Information on Zyprexa.
(a)

If a Signatory Attorney General believes the Reprint
Containing Off-Label Information to be
disseminated does not meet the Clinical Necessity
Exception, then the State will provide Lilly with
written notice within 30 business days and provide
Lilly an opportunity to discuss its desired use of the
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Reprint Containing Off-Label Information pursuant
to the limited exception.
(b)

If the State and Lilly do not come to a resolution,
then the State may initiate legal action to prevent
the dissemination o f the Reprint Containing OffLabel Information by Lilly Non-Medical personnel.

(c)

If the State initiates legal action to prevent the
dissemination of the Reprint Containing Off-Label
Information by Lilly Non-Medical personnel, Lilly
shall not use Lilly Non-Medical personnel to
disseminate such Reprint Containing Off-Label
Information in that State until the issue has been
resolved.

3.
Nothing in this Judgment shall preclude Lilly from disseminating reprints
which have an incidental reference to Off-Label information. If reprints have an incidental
reference to Off-Label information, such reprints shall contain the disclosure required by Section
ILD.2.b(i) in a prominent location, as defined above.
E.

Health Care Economic Information

1.
Nothing in this Judgment shall preclude Eli Lilly from providing Health
Care Economic Information to a formulary committee or other similar entity or its members in
the course o f the committee or entity carrying out its responsibilities for the selection of drugs for
managed care or other similar organization pursuant to the standards of FDAMA Section 114 if
the information directly relates to an approved indication for Zyprexa and if it is based on
competent and reliable scientific evidence.
III.

Continuing Medical Education (CME) and Grants

A.
The following subsections shall be effective for six years from the Effective Date
o f this Judgment.
B.
Lilly shall disclose information about grants, including CME grants, regarding
Zyprexa consistent with the current disclosures o f the Lilly Grant Office Registry at
www.lillygrantoffice.com (hereinafter, “LGO website”) or as required by applicable law.
1.
Lilly shall maintain this information on the LGO website once posted for
at least two years and shall maintain the information in a readily accessible format for review by
the States upon written request for a period o f five years.
C.
The Lilly Grant Office shall manage all requests for funding related to CME
regarding Zyprexa. Approval decisions shall be made by the Lilly Grant Office alone, and shall
be kept separate from the Lilly Sales and Lilly Marketing organizations.
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D.
Lilly shall not use grants to Promote Zyprexa. This provision includes, but is not
limited to, the following prohibitions:
1.
Lilly Sales and Lilly Marketing personnel shall not initiate, coordinate or
implement grant applications on behalf o f any customer or HCP;
2.
Lilly Sales and Lilly Marketing personnel shall not be involved in
selecting grantees or CME-funded speakers; and
3.
Lilly Sales and Lilly Marketing personnel shall not measure or attempt to
track in any way the impact of grants or speaking fees on the participating HCPs’ subsequent
prescribing habits, practices or patterns.
E.
Lilly shall not condition funding o f a CME program grant request regarding
Zyprexa upon the requestor’s selection or rejection o f particular speakers.
F.
Lilly shall not suggest, control, or attempt to influence selection of the specific
topic, title, content, speakers or audience for CMEs regarding Zyprexa, consistent with ACCME
guidelines.
G.
Lilly Sales and Lilly Marketing personnel shall not approve grant requests
regarding Zyprexa, nor attempt to influence the Lilly Grant Office to reward any customers or
HCPs with grants for their prescribing habits, practices or patterns.
H.
Lilly shall contractually require the CME provider to disclose to CME program
attendees Lilly’s financial support o f the CME program and any financial relationship with
faculty and speakers at such CME. As part o f the disclosure o f a financial relationship with
faculty and speakers, Lilly shall contractually require the CME program to identify the URL o f a
Lilly website, and reference that website as the source for further information concerning grant
funding regarding Zyprexa.
I.
After the initial delivery of a CME program, Lilly shall not fund the same
program, nor shall it provide additional funding for re-distribution o f the same program, if it
knows that the program’s speakers are Promoting Zyprexa for Off-Label uses.
IV.

Payments to Consultants and Speakers

A.
The following subsections shall be effective for six years from the Effective Date
o f this Judgment.
B.
This Section shall apply to U.S. based Consultants and Promotional Speakers to
the Lilly Marketing organization.
C.
Lilly shall provide to each Signatory Attorney General, in an electronic
spreadsheet format, a list o f HCP Promotional Speakers and Consultants who were paid by Lilly
any taxable income in excess o f $ 100 for Promotional speaking and/or Consulting performed for
Lilly in the U.S., a list o f all titles o f Promotional presentations made, and the following
additional information with respect to each individual Promotional Speaker and/or Consultant:
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1.

total compensation from Lilly for any Consulting or Promotional speaking

2.

total number o f Promotional speaking events paid for by Lilly;

fees;

3.
contact purposes;

the state tile Promotional Speaker/Consultant has provided to Lilly for

4.
presentations; and

the state(s) in which the Promotional Speaker gave the Promotional

5.

any other compensation from Lilly as set forth in 1RS Form 1099.

j

On or before July 1,2009, Lilly shall provide the data requested in Nos. 1-4 for the period
January 1 ,2009-March 31,2009. On or before October 1,2009, Lilly shall provide the data
requested in Nos. 1-4 for the period April 1,2009-June 30, 2009. On or before January 1,2010,
Lilly shall provide the data requested in Nos. 1-4 for the period July 1 ,2009-September 30,
2009. On or before April 1, 2010 and on or before April 1 o f each subsequent year, Lilly shall
provide the data requested in Nos. 1-5 for the full preceding calendar year.
D.
Lilly shall disclose to the Promotional Speaker or Consultant that the information
in Section TV.C. above may be disclosed.
V.

Product Samples

A.
The following subsections shall be effective for six years from the Effective Date
of this Judgment.
B.
Lilly Sales representatives may only sample Zyprexa to a HCP whose clinical
practice is consistent with the product’s current Labeling. Currently, Lilly samples Zyprexa to
the following practices: emergency medicine, family practice, general practice, internal
medicine, and psychiatry.
C.
If a HCP whose clinical practice is inconsistent with the product’s Labeling
requests samples, Lilly personnel shall refer thé practitioner to 1-800-LillyRx where the
practitioner can speak directly with a Lilly representative who will provide answers to their
questions about Zyprexa and may provide them with samples if appropriate (i.e., if the physician
requests the sample for an on-label use).
VI.

Clinical Research

A.
Lilly shall report research regarding Zyprexa in an accurate, objective and
balanced manner as follows or as required by applicable law:
1.
To the extent permitted by the National Library o f Medicine and as
required by the FDA Amendments Act (Public Law No. 110-85), Lilly shall register clinical
trials and submit results to the registry and results data bank regarding Zyprexa as required by
the FDA Amendments Act and any accompanying regulations that may be promulgated pursuant
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to that Act. With respect to Zyprexa, Lilly will register on a publicly accessible website the
initiation o f all Lilly-sponsored Phase II, III, and IV clinical trials beginning after July 1, 2005
and will post results on a publicly accessible website of all Lilly-sponsored Phase II, III and IV
clinical trials that were completed after July 1,2004. Nothing in this paragraph shall be
construed to exempt Lilly from full compliance with Maine’s Prescription Drug Clinical Trial
Reporting Rule: DHHS Rule 10-144 ch. 275 AG Rule 26-0259 Ch. 111.
B.
When presenting information about a clinical study regarding Zyprexa in all
Promotional Materials, Lilly shall not do any o f the following in a manner that causes the
Promotional Materials to be false or misleading:
1.
present favorable information or conclusions from a study that is
inadequate in design, scope, or conduct to furnish significant support for such information or
conclusions;
2.
use the concept o f statistical significance to support a claim that has not
been demonstrated to have clinical significance or validity, or fails to reveal the range of
variations around the quoted average results;
3.
use statistical analyses and techniques on a retrospective basis to discover
and cite findings not soundly supported by the study, or to suggest scientific validity and rigor
for data from studies the design or protocol o f which are not amenable to formal statistical
evaluations;
4.
present the information in a way that implies that the study represents
larger or more general experience with the drug than it actually does; or
5.
use statistics on numbers o f patients, or counts o f favorable results or side
effects, derived from pooling data from various insignificant or dissimilar studies in a way that
suggests either that such statistics are valid if they are not or that they are derived from large or
significant studies supporting favorable conclusions when such is not the case.
VII.

Terms Relating to Payment

A.
No later than 30 days after the Effective Date of this Judgment, Lilly shall pay
$62 million to be divided and paid by Lilly directly to each Signatory Attorney General o f the
Multistate Working Group in an amount to be designated by and in the sole discretion o f the
Multistate Executive Committee. Said payment shall be used by the States as and for attorneys’
fees and other costs o f investigation and litigation, or to be placed in, or applied to, the consumer
protection enforcement fund, including future consumer protection enforcement, consumer
education, litigation or local consumer aid fund or revolving fund, used to defray the costs o f the
inquiry leading hereto, and may be used to fund or assist in funding programs directed at mental
illness treatment, including but not limited to education and outreach or for other uses permitted
by state law, at the sole discretion o f each Signatory Attorney General. The Parties acknowledge
that the payment described herein is not a fine or penalty, or payment in lieu thereof.
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VIII.

Conflicts

A.
If subsequent to the Effective Date o f this Judgment, the federal government or
any state, or any federal or state agency, enacts or promulgates legislation or regulations with
respect to matters governed by this Judgment that creates a conflict with any provision of the
Judgment and Eli Lilly intends to comply with the newly enacted legislation or regulation, Eli
Lilly shall notify the Attorneys General (or the Attorney General of the affected state) of the
same. If the Attorney General agrees, he/she shall consent to a modification o f such provision of
the Judgment to the extent necessary to eliminate such conflict. If the Attorney General disagrees
and the Parties are not able to resolve the disagreement, Eli Lilly shall seek a modification from
an appropriate court o f any provision o f this Judgment that presents a conflict with any such
federal or state law or regulation. Changes in federal or state laws or regulations with respect to
the matters governed by this Judgment, shall not be deemed to create a conflict with a provision
o f this Judgment unless Eli Lilly cannot reasonably comply with both such law or regulation and
the applicable provision o f this Judgment.
B.
If, subsequent to the Effective Date o f this Judgment, the laws or regulations of
the United States, or the draft or final FDA Guidances for Industry, are changed so as to
expressly authorize conduct that is expressly prohibited by this Judgment, then such conduct
shall not constitute a violation o f this Judgment. Provided however, if Lilly intends to engage in
the expressly authorized conduct, Lilly shall notify the Attorneys General (or the Attorney
General o f the affected state) within 30 business days prior to any change.
IX.

Release

A.
By its execution o f this Judgment, State o f Maine releases and forever discharges,
to the fullest extent permitted by law, Eli Lilly and all of its past and present subsidiaries,
divisions, affiliates, co-promoters, controlled joint ventures, predecessors, successors, and
assigns and each and all of their current and former officers, directors, shareholders, employees,
agents, contractors, and attorneys (collectively, the “Released Parties”) o f and from the
following: all civil claims, causes of action, damages, restitution, fines, costs, attorneys fees, and
penalties that the Maine Attorney General could have asserted against the Released Parties under
the Maine Unfair Trade Practices Act, successor statutes, or common law claims concerning
unfair, deceptive or fraudulent trade practices impacting consumers related to any conduct that
has occurred at any time up to and including the Effective Date o f this Judgment arising from
the Covered Conduct that is the subject o f this Judgment (collectively, the “Released Claims”).
B.
Notwithstanding any term o f this Judgment, specifically reserved and excluded
from the Released Claims as to any entity or person, including Released Parties, are any and all
o f the following:
1.
Any criminal liability that any person or entity, including Released Parties,
has or may have to the State o f Maine;
2.
Any civil or administrative liability that any person or entity, including
Released Parties, has or may have to the State of Maine that is not expressly covered by the
release in Section IX.A. above, including but not limited to any and all o f the following claims:
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X.

a.

State or federal antitrust violations;

b.

Reporting practices, including “best price,” “average wholesale
price,” or “wholesale acquisition cost;”

c.

Medicaid violations, including federal Medicaid drug rebate statute
violations, Medicaid fraud or abuse, Medicaid-related common law
claims; and/or kickback violations related to any State’s Medicaid
program;

d.

State false claims violations;

e.

actions o f state program payors arising from the purchase of
Zyprexa, except for the release o f civil penalties under the state
consumer protection laws; and

f.

Any liability under the State of Maine’s above-cited Consumer
Protection Law which the Released Parties have or may have to
individual consumers.

Cure Provision

A.
The Parties agree that a State will provide Lilly with written notice if it believes
that Lilly is in violation o f any o f its obligations under the Judgment (“Notice”). Lilly shall have
30 business days after the date o f receipt o f the Notice to demonstrate to the State’s satisfaction
that:
1.
Lilly is in compliance with the obligations o f the Judgment cited by that
State as being violated;
2.
the violation has been cured, including, but not limited to, by remedial
actions having been taken against an employee for actions inconsistent with this Judgment; or
r

3.
the alleged violation cannot be cured within the 30 business day period,
but that: (a) Lilly has begun to take action to cure the violation; (b) Lilly is pursuing such action
with due diligence; and (c) Lilly has provided a reasonable timetable for curing the violation.
B.
Except as set forth in Section X.D. below, the State may not take any action
during the 30 business day cure period. Nothing shall prevent the State from agreeing in writing
to provide Eli Lilly with additional time beyond the 30 business days to respond to the notice.
C.
The State may not take any action during which a modification request is pending
before a court pursuant to Section VIII.A, except as provided for in Section D below.
D.
Nothing prohibits a State from taking actions necessary to protect public health
and safety as provided by applicable law.
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XI.

General Provisions

A.
This Judgment represents the full and complete terms o f the settlement entered
into by the Parties hereto. In any action undertaken by the Parties, no prior versions of this
Judgment, no prior versions o f any o f its terms, that were not entered by the Court in this
Judgment, may be introduced for any purpose whatsoever.
B.
This Court retains jurisdiction o f this Judgment and the Parties hereto for the
purpose of enforcing and modifying this Judgment and for the purpose o f granting such
additional relief as m aybe necessary and appropriate.
C.
This Judgment may be executed in counterparts, and a facsimile or .pdf signature
shall be deemed to be, and shall have the same force and effect as, an original signature.
D.
All Notices under this Judgment shall be provided to Nina Gussack, Paul Kalb,
and the General Counsel o f Eli Lilly and Company by Overnight Mail at:
Nina Gussack
Pepper Hamilton
3000 Two Logan Square
Eighteenth and Arch Streets
Philadelphia, PA 19103-2799
Paul E. Kalb
Sidley Austin LLP
1501 K Street, NW
Washington, DC 20005
General Counsel
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285
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XII.

SIGNATURES

FOR ELI LILLY:

^Michael J. Harmigton
Deputy General Counsel
Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285
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Nicholas Gess, Bar No. 002504
Bingham McCutchen LLP
2020 K Street NW
Washington, DC 20006
202-373-6218
202-373-6491-Fax
J
Nicholas.gess@bingham.com
Attorney for Eli Lilly and Company

Date:

£
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FOR THE STATE:

ATTORNEY GENERAL G. STEVEN ROWE

By.

Date:

»V î j Q -y/à~-^~
Christina M. Moylan, Assistant Attoiâey General
Office o f the Maine Attorney General
111 Sewall Street
6 State House Station
Augusta, Maine Ö4333-0006
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